Lundbeck

ImaginAb, Lundbeck to collaborate in neurodegeneration

Wednesday, October 10, 2012 12:49 PM

ImaginAb, an Inglewood, Calif.-based clinical-stage company developing in vivomolecular imaging agents, has entered into a collaboration and commercialization agreement with Lundbeck, an international pharmaceutical company, on a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

More... »

Lundbeck files for EMA approval of vortioxetine for depression

Friday, September 21, 2012 01:34 PM

H. Lundbeck, an international pharmaceutical company, has submitted a marketing authorization application (MAA) to the EMA for the approval of the investigational multimodal antidepressant vortioxetine (Lu AA21004), and the dossier has been accepted for review.

More... »

Lundbeck, CHDI Foundation collaborate on Huntington’s disease

Tuesday, May 22, 2012 10:23 AM

Lundbeck, a pharmaceutical company based in Deerfield, Ill. and CHDI Foundation, a not-for-profit biomedical research organization, have formed a research collaboration to investigate a targeted therapy for Huntington’s disease.

More... »

The CenterWatch Monthly, April 2012

Sunday, April 1, 2012 06:30 AM

Global sites see growth in trials, revenue, staffing

More... »

Otsuka, H. Lundbeck partner to develop innovative medicines

Friday, November 11, 2011 11:02 AM

Otsuka Pharmaceutical and H. Lundbeck have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide.

More... »

Lunudbeck to invest $16 million in Proximagen

Thursday, September 29, 2011 01:00 PM

Danish pharmaceutical group Lundbeck is to invest $6.1 million in British peer Proximagen Group as part of a strategic partnership, the companies said, according to Reuters.

More... »

Lundbeck Canada donates $2.7 million towards depression study

Tuesday, August 30, 2011 10:25 AM

The Canadian subsidiary of neurological disease specialist Lundbeck has donated $2.7 million towards a nationwide study aimed at identifying biomarkers of major depression and bipolar disorder, according to PharmaTimes.

More... »

Lundbeck cuts R&D as sales continue to rise

Wednesday, August 10, 2011 12:43 PM

Lundbeck saw its sales rise 9% in the second-quarter, continuing a run of revenue growth on the back of gains for Alzheimer's disease treatment Ebixa and a good showing for antidepressant Lexapro in the US, according to PharmaTimes.

More... »

Advanced Clinical names executive director

Friday, July 15, 2011 10:40 AM

Advanced Clinical, a provider of clinical research solutions, has named Eman Albazzaz Executive Director of Regulatory Affairs, to lead Advanced Clinical’s regulatory and pharmacovigilance efforts.

More... »